Business Wire

DC-DALBERG-ADVISORS

25.3.2024 06:01:31 CET | Business Wire | Press release

Share
Dalberg Awarded 5-Year Contract to Strengthen United States Agency for International Development's (USAID) Work With the Private Sector

Dalberg Advisors (https://Dalberg.com/) has announced the award of the Private Sector Engagement Strategic Collaboration and Leading-Edge Engagement (“PSE SCALE”) program, a framework agreement of advisory services that will support the U.S. Agency for International Development (USAID: https://www.USAID.gov/) to engage the private sector to achieve development and humanitarian outcomes. Through the five-year, $99.1-million contract, Dalberg and its partners will support USAID to accelerate private sector partnerships around the world and transform the Agency’s capacity to work with the private sector.

PSE SCALE is an extension of over 20 years of efforts by USAID to increasingly partner and invest with the private sector to achieve the Agency’s development and humanitarian goals. It represents the flagship mechanism to upgrade USAID’s capacity to work with the private sector and will provide a range of technical and advisory services to USAID Missions and operating units seeking to expand or accelerate private sector engagement. Activities include support for strategy development, organizational effectiveness, workforce development, partnership facilitation, market research and more. In an increasingly complex global environment, the objective of this work is to position USAID as a capable and vital partner to companies seeking to drive growth and innovation in new markets, reduce risk, and advance sustainability goals.

Dalberg and a consortium of partners— 60 Decibels (https://60Decibels.com/), CrossBoundary (https://CrossBoundary.com/), Vera Solutions (https://VeraSolutions.org/), and Social Solutions International (https://www.SocialSolutions.biz/)—will provide a comprehensive and integrated suite of services that are delivered on-demand and in response to needs and opportunities in any operating unit across USAID. The team collectively brings decades of experience in serving clients globally across the public and private sectors on a wide range of sustainable development issues.

“Dalberg is thrilled to be supporting USAID in deepening its collaboration with the private sector. Our experience and local networks across markets in Africa, Asia, and Latin America makes Dalberg a natural partner for USAID,” said Gaurav Gupta, Dalberg’s Global Managing Partner. “And with over 1,100 clients across the public and private sectors, we have a long track record of designing successful cross-sector partnerships that help all parties to advance their goals.”

Distributed by APO Group on behalf of Dalberg Advisors.

Download image: https://apo-opa.co/4cw4lVk (Illustration of multi-sectorial activities)

About Dalberg Advisors:

Dalberg Advisors is a strategic advisory firm that combines private sector strategy skills and analytical capabilities with deep knowledge and networks across emerging and frontier markets. Dalberg works actively across the public, private, and philanthropic sectors to help clients achieve their goals and has over 500 employees across 25 locations in Africa, Asia-Pacific, Latin America, Europe, and the U.S. Dalberg Advisors is part of the Dalberg Group, which comprises a collection of mission-driven enterprises—Dalberg Advisors, Dalberg Data Insights, Dalberg Design, Dalberg Media, Dalberg Implement, Dalberg Research—and the not-for-profit, Dalberg Catalyst.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240324686686/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye